Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

NCT06016972 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open Angle Glaucoma (POAG)
Primary Open Angle Glaucoma of Both Eyes
Primary Open-Angle Glaucoma, Unspecified Eye
Ocular Hypertension (OHT)

Interventions

DRUG: Experimental: QLS-111 ophthalmic solution, (0.015%)
DRUG: Experimental: QLS-111 ophthalmic solution, (0.03%)
DRUG: Experimental: QLS-111 ophthalmic solution, (0.075%)
OTHER: QLS-111 ophthalmic vehicle solution

Sponsor

Qlaris Bio, Inc.